NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
Neuphoria Therapeutics Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026
$3.31+0.01 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $17.90M
- P/E (TTM)
- –
- Dividend yield
- –
Neuphoria Therapeutics Inc. revenue by segment
By business segment
By product or service
By region
From the segment and revenue-disaggregation notes of Neuphoria Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.